Magnifi Communities

Energy suppliers are poised to receive increased interest as we navigate various macroeconomic influences and geopolitical disruptions, each bearing significant relevance to energy supply costs and profitability. Renewables have an element of unpredictability to the scenario, potentially distinguishing themselves from conventional energy providers regarding pricing and core offerings.
Headquartered in London, United Kingdom, ReNew Energy Global Plc (RNW) has marked its footprint in the Indian market, emerging as a noteworthy player in the renewable energy sector. This renewable energy producer primarily focuses on wind and solar energies, illustrating a concerted effort towards sustainable solutions. As of September 2023, its clean energy portfolio stands at ~13.8 GW of capacity.
The company has showcased consistent and improved performance much to the satisfaction of its shareholders, such as displayed in its impressive second-quarter results that substantially surpassed top and bottom-line estimates.
Looking ahead, RNW plans to commission between 1.75 GW and 2.25 GW by the end of the fiscal year 2024. Management projects EBITDA growth of ~35%+ per share in the fiscal year 2025.
Despite contending with the adverse impacts of the pandemic, RNW has persevered unwaveringly towards its financial objectives. With a profit after tax of $45 million in the second quarter, the company recorded one of its highest profits.
India’s renewable energy sector is thriving, propelled by a rising power demand, escalating renewable energy auctions, and shifting toward complex projects. Positioned at the vanguard of this transformative revolution, RNW maintains capital discipline while skillfully leveraging market opportunities.
The company thrives under the swift escalation in power demand and energy supply shortfalls. Softening solar module prices paints a promising backdrop for this renewable energy developer.
A critical trend identified within the industry is the escalating complexity of projects and customized solutions tailored to distribution companies’ specifications. This evolution presents an advantageous opportunity for RNW, a pioneer with the most comprehensive wind development portfolio. Their leadership status empowers them to address the distinct electricity supply profiles required accurately.
RNW has attained important projects through power purchase agreements (PPAs) and letters of awards (LoAs). These include a PPA with GUVNL, Gujarat’s Distribution Entity, for a 400-megawatt capacity and receipt of LoAs for an additional 2.9 gigawatts. Such undertakings will significantly bolster RNW’s long-term earning potential upon successful completion.
RNW is proactively exploring opportunities to broaden its portfolio to meet the rising demand for renewable energy. The company remains dedicated to its capital allocation and strategies that foster value creation.
This commitment serves as testimony to the company’s knack for attracting investments and strategic partnerships at beneficial valuations. In slightly above two years, RNW drew in an impressive $565 million via asset recycling, facilitating the use of these funds towards more lucrative opportunities.
However, not all seems well for the alternative energy company, and hence, investors could exercise caution moving forward.
RNW’s trailing-12-month Return on Common Equity (ROCE) of 2.75% is lower than the industry average of 9.10%. Also, the company resorts to substantial amounts of debt to finance its business operations. For the fiscal second quarter that ended September 30, 2023, its gross debt was $7.07 billion. This results in a strikingly high debt-to-equity ratio of 4.74.
A lower ROCE could imply that a company could still improve its returns through leverage, considering it has low debt levels. For a company like RNW, which pairs low ROCE with considerable gross debt, investors may want to proceed cautiously, given the heightened risk involved.
Another critical measure of a company’s financial health is its current ratio, gauging its capability to meet short-term liabilities. RNW’s ratio, which is at a low of 0.88, raises red flags about the company’s short-term liquidity situation.
Institutions hold roughly 55.6% of RNW shares. Of the 96 institutional holders, 44 have decreased their positions in the stock. Moreover, 20 institutions have sold out their positions (1,628,328 shares).
However, Wall Street analysts expect the stock to reach $8.63 in the next 12 months, indicating a potential upside of 37.2%. The price target ranges from a low of $8 to a high of $9.25.
Street expects RNW’s revenue for the fiscal third quarter ending December 2023 to come at $188.79 million, while EPS is expected to be negative at $0.18.
Bottom Line
The imminent growth of the renewable energy sector presents a promising landscape, and RNW is strategically situated to capitalize on this burgeoning potential. With a robust pipeline of projects, a rigorous approach, and a dedication to innovative solutions, RNW spearheads the progressive shift toward renewable energy in India.
RNW is a high-margin, low-capital turnover business, demanding significant reinvestment to sustain its market competitiveness.
Business growth typically necessitates financial investment, which can originate from sources such as retained earnings, issuance of new shares, or procuring loans. The ROCE mirrors the use of investment capital in the first two scenarios. In the case of borrowing, the resultant debt will augment returns without affecting the shareholders’ equity, thus artificially enhancing the perceived ROCE.
In RNW’s context, prospective investors could tread cautiously and wait for a better entry point in the stock, given the high debt levels and low ROCE. Furthermore, the alarming Net Operating Debt/Adjusted EBITDA (TTM) ratio of 6.21x serves as a “red flag” and signals potential financial strain in the corporation’s future.

The U.S. banking sector is undergoing a significant transformation, echoing societal shifts that saw payphones and video stores disappear into obsolescence. The silent erosion of bank branches has been transpiring within the financial sector for over a decade, beginning in 2010 and intensifying in recent years.
According to the U.S. Federal Deposit Insurance Bureau (FDIC), large commercial U.S. bank venues have sharply declined from 8,000 in 2000 to 4,236 by 2021, further dwindling to 4,194 in 2022. Normative banking procedures have been remarkably altered within this period, as evidenced by the dwindling count of U.S. branch bank sites directly linked to mainstream banks.
As per S&P Global Market Intelligence, U.S. banks closed 149 branches and launched 49 in March, culminating in an overall 78,588 operational branches.
Should this declining trend in bank branch numbers sustain momentum, bank branches could disappear within the next ten years. The Self Financial estimates that the U.S. bank branches will dip dramatically from about 60,000 in 2023 to 15,660 in 2030, with numerical reductions continuing until the projected total elimination of bank branches by 2034.
The national shift is exemplified by the Bank of America Corporation (BAC), the nation’s second-largest bank by assets, mapping plans to reduce the extent of its physical footprint through the closure of several branches across the U.S.
According to the OCC’s weekly circular, the Charlotte, North Carolina-based bank is actively pursuing authorization from the Office of the Comptroller of the Currency to close the branches. The applications were filed with the regulator on October 5
It has gotten into the act, closing 5% of its physical locations in Philadelphia. The anticipated closures will have a significant impact nationwide.
Let’s first understand the reason behind the closures and identify why this trend has seen a significant acceleration over the past few years.
Recent years have seen an accelerated rate of bank branch closures, amplified by changing consumer behaviors and evolving banking infrastructures. The advent of the COVID-19 pandemic and subsequent social distancing mandates in 2020 and 2021 catalyzed this trend. As foot traffic was reduced to near zero at local branches, there was a soaring increase in the adoption of digital products and banking services.
Banks are directing more resources toward enhancing their online platforms to meet customer demands for digital banking services. Consequently, the need for physical branches has diminished, prompting banks to adjust their physical footprints constantly. The practical implications include enhanced bottom lines fueled by cost savings and greater investment into technological advancements.
As banks become more digitally savvy, the industry anticipates a continuous drop in the number of branches in operation.
The banking industry’s consolidation through mergers and acquisitions has also been instrumental in accelerating this trend. Banks often buy out rivals to reduce overlapping staff, services, and facilities expenses. The result is increased profitability, with the closure of redundant branches being key to these cost-saving measures.
Large regional and national banks predominantly lead branch closure as their extensive networks provide ample cost-reduction opportunities. Nevertheless, banks of all sizes are progressively steering their investments away from physical locations and toward digital platforms.
During BAC’s quarterly earnings call, CEO Brian Moynihan shared that the company’s consumer business headcount had decreased from around 100,000 to roughly 60,000 – a decline that continues as digital banking experiences an increased adoption.
As of 2022, a clear preference for online banking among U.S. adults at 78% was evident, while only 29% preferred traditional, in-person banking. The closure of BAC branches is unlikely to impact individual accounts directly; the bank provides several channels that allow customers to access and manage their accounts, including online banking, mobile banking, ATMs, and customer service centers.
However, there is an underlying concern that BAC could alienate less tech-proficient customers like senior citizens or those with disabilities. In certain communities, the closure of neighborhood banks has caused substantial damage to local economies and heightened existing financial inequities.
The ramifications of banks disappearing from communities extend beyond convenience — for instance, residents are forced to commute further to make elementary transactions such as deposits or withdrawals. This could potentially instigate a shift of these customers to other banking institutions.
BAC might consider implementing measures such as a fee waiver for retained customers or an added fee for closing an account within a specified timeframe. Both strategies could deter clients from changing banks and concurrently generate some revenue.
Let’s look at other factors investors could consider before investing in BAC.
BAC’s investment holdings presently display considerable unrealized losses, falling short of competitive rates since 2007. As of June 30, 2023, paper losses on their debt securities exceeded $109 billion, which surged to $136.22 billion by the end of the third quarter.
With approximately $603.37 billion entangled in held-to-maturity securities, the bank’s considerable holdings in these low-yielding assets curb its capability to amplify profits through cash investments in money markets or higher-return assets.
BAC is anticipated to witness lower overall yields on its securities book for the foreseeable future. However, analysts do not expect the necessity for the bank to liquidate these holdings, thus avoiding additional losses.
The bank’s securities portfolio tilts heavily toward debt maturing after ten years. If the Federal Reserve implements another potential rate hike, the valuation of these holdings could decline further, possibly leading to a decrease in earnings from BAC’s investments.
Conversely, if interest rates stabilize or gradually decline, share prices may improve, given that the long-term securities held by the bank are expected to increase in value.
Furthermore, BAC reported a 4.5% year-over-year increase in net interest income in the fiscal third quarter of 2023, exceeding analyst expectations. However, it still lags behind its competitors, JP Morgan and Wells Fargo.
BAC has amassed unrealized losses amounting to $131.6 billion on securities, and even with government guarantees, it does raise red flags. Yet, with over $3 trillion in assets and $1.9 trillion in deposits as of September 30, 2023, BAC has sufficient financial stability to weather the storm.
For the average bank customer, an unrealized loss of this magnitude may not be of immediate concern; however, it does present a potential issue for investors. Coupled with the advantage of its massive insured customer deposits, BAC has protection against the kind of deposit flights that regional banks have undone.
Furthermore, BAC’s stocks declined about 11% year-to-date but trades above the 50-, 100-, and 200-day moving averages. However, Wall Street analysts expect the stock to reach $33.76 in the next 12 months, indicating a potential upside of 14.2%. The price target ranges from a low of $27 to a high of $51.
Furthermore, several institutions have recently modified their BAC stock holdings. Institutions hold roughly 69.9% of BAC shares. Of the 2,771 institutional holders, 1,148 have increased their positions in the stock. Moreover, 146 institutions have taken new positions (37,323,335 shares).
Bottom Line
BAC continues to streamline its operations, shifting toward a digital business platform as it grapples with decreased branch traffic and escalating maintenance costs.
The strategic shift may leave customers without access to a local branch, highlighting critical considerations for the effectiveness of the traditional cash system and underscoring the potential impact on sections of marginalized society that depend heavily on physical banking services.
Additionally, the prevailing macroeconomic volatility and high interest rates, projected to persist, raise concerns about an increase in BAC’s unrealized losses, coupled with the potential customer transition to treasuries or Money Market Funds.
Despite these challenges, shareholders can take solace in knowing that BAC’s management seems to be performing skillfully. Additionally, the era of high interest rates has resulted in a net benefit so far.
Interestingly, BAC’s interest-bearing deposits reached $1.31 trillion, reflecting depositor trust in its financial standing.
Although investor sentiment slumped over the past year, BAC maintains an impressive balance sheet fortified by sturdy profitability. Furthermore, it offers an enticing dividend yield of 3.25% on the current share price.
So, it could be wise for investors to hold on to the stock and look forward to a gradual capital appreciation. The unrealized losses might be less daunting for long-term investors focused on continuous dividend payouts.
However, investors seeking steady revenue should proceed with caution. While BAC’s forward dividend yield stands at an attractive 3.25%, exceeding the four-year average yield of 2.44%, it still falls short of the 3.78% sector median.
Considering prevailing circumstances, it may be prudent for new investors to wait for a better entry point in the stock.

Shares of CRISPR Therapeutics AG (CRSP) have gained more than 40% over the past three months against the industry’s decline of nearly 11%. Moreover, the stock has surged more than 80% over the past month.
The gene-editing stock continues to enjoy accelerated momentum from a key regulatory approval. On November 16, CRISPR Therapeutics and its partner, Vertex Pharmaceuticals Incorporated (VRTX), announced that the United Kingdom-based Medicines and Healthcare Products Regulatory Agency (MHRA) granted conditional market authorization for CASGEVY™.
CASGEVY has been authorized for the treatment of patients 12 years of age and older with sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) or transfusion-dependent beta-thalassemia (TDT), for whom a human leukocyte antigen (HLA) matched related hematopoietic stem cell donor is unavailable. There are nearly 2,000 patients eligible for CASGEVY in the United Kingdom.
This represents the first regulatory authorization of a CRISPR-based gene-editing therapy worldwide and offers a new option for eligible patients waiting for innovative therapies. Notably, this approval made CASGEVY the first approved product in CRISPR Therapeutics’ portfolio.
Further, CRSP and VRTX’s Biologics License Applications (BLAs) seeking approval for exa-cel for treating SCD and TDT indications are currently under review in the U.S.
The U.S. Food and Drug Administration (FDA) granted priority review to the BLA filing for exa-cel in SCD, and the exa-cel filing in TDT indication was accepted for a standard review. A final decision on the BLAs for exa-cel in SCD and TDT indications is anticipated by December 8, 2023 and March 30, 2024, respectively.
In October, an FDA Cellular, Tissue, and Gene Therapies Advisory Committee appeared satisfied with CRISPR/Vertex’s regulatory filing on exa-cel in the SCD indication. This development will likely move the gene therapy closer to gaining potential marketing approval from the agency.
Both the SCD and TDT have significant unmet medical needs. A potential approval for exa-cel in the U.S. will be a major boost for CRSP and will likely drive the stock higher in the upcoming quarters.
Meanwhile, the company is developing CRISPR candidates to create next-generation CAR-T cell therapies for treating hematological and solid-tumor cancers. Clinical trials are ongoing for its CAR-T product candidates, CTX110 and CTX 112, targeting CD10 in B-cell malignancies.
In addition, CRSP is evaluating the safety and efficacy of CTX130 in two ongoing phase I studies for treating various solid tumors like renal cell carcinoma and certain T-cell and hematologic malignancies. VCTX211, an allogeneic, gene-edited, stem cell-derived product candidate for treating Type 1 Diabetes, has been undergoing clinical trial.
A clinical trial has also been initiated for CTX310, targeting angiopoietin-related protein 3 (ANGPTL3).
Let’s discuss several factors that could impact CRSP’s performance in the near term:
Deteriorating Financials For the third quarter that ended September 30, 2023, CRSP reported nil total revenue, missed the analysts’ estimate of $7.96 million. That compared to revenue of $94 thousand in the same quarter of 2022. The company’s loss from operations came in at $132.41 million. Also, it reported a net loss before income taxes of $111.74 million for the quarter.
Furthermore, CRSP reported a third-quarter net loss of $112.15 million. The company’s net loss per common share came in at $1.41, narrower than the consensus estimate of $1.95.
The company’s cash, cash equivalents, and marketable securities were $1.74 billion as of September 30, 2023, compared to $1.87 billion as of December 31, 2022. The decline in cash of $128.60 million was primarily driven by operating expenses. During the third quarter, CRSP’s operating expenses were $132.41 million.
Unfavorable Analyst Estimates
Analysts expect CRSP’s revenue to significantly increase year-over-year to $104.31 million for the fourth quarter ending December 2023. However, the company is expected to report a loss per share of $0.22 for the ongoing quarter. For the fiscal year 2023, the company’s loss per share is estimated to be $3.46.
Further, CRSP’s revenue for the fiscal year 2024 is expected to decline 46.4% year-over-year to $148.08 million. Street expects the company to report a loss per share of $6.43 over the next year.
Elevated Valuation
In terms of forward EV/Sales, CRSP is currently trading at 15.16x, 370.6% higher than the industry average of 3.22x. The stock’s forward Price/Sales of 20.58x is 464% higher than the industry average of 3.65x. Additionally, CRSP’s forward Price/Book multiple of 3.34 is 40.5% higher than the industry average of 2.44.
Decelerating Profitability
CRSP’s trailing-12-month gross profit margin of negative 201.7% compared to the 56.62% industry average. Moreover, the stock’s trailing-12-month EBITDA margin and net income margin of negative 236.98% and 207.95% compared unfavorably to the respective industry averages of 5.29% and negative 5.75%.
Furthermore, the stock’s trailing-12-month levered FCF margin of negative 119.66% is lower than the industry average of 0.11%. CRSP’s trailing-12-month asset turnover ratio of 0.08x is 80.5% lower than the industry average of 0.39x.
Stiff Competition
Heightened competition remains a significant headwind, with several other biotech companies using the CRISPR/Cas9 gene-editing technology to address several ailments. The main competitors of CRISPR Therapeutics include Verve Therapeutics, Inc. (VERV), eGenesis, Editas Medicine, Inc. (EDIT), Caribou Biosciences, Inc. (CRBU), Intellia Therapeutics, Inc. (NTLA), and Beam Therapeutics Inc. (BEAM).
EDIT, developing its lead pipeline candidate EDIT-301, employs CRISPR gene-editing in a phase I/II study for SCD and TDT indications. A potential approval for the candidate developed by EDIT will likely pose increased competition for CRSP in the future.
Bottom Line
CRSP, one of the first companies formed to use the CRISPR gene editing platform to develop medicines and therapies for treating several rare and common diseases, continues to report losses. While the third-quarter loss was narrower than expected, the company’s revenue missed analysts’ expectations.
Despite its deteriorating fundamentals, shares of CRSP have been surging lately on the news of winning the first-ever regulatory approval for a CRISPR-based gene-editing drug, CASGEVY (exa-cel). Exa-cel is the first therapy to emerge from a strategic partnership between CRSP and VRTX for patients with severe sickle cell disease.
In the upcoming months, the FDA will decide whether to approve exa-cel. And this decision by the FDA will determine the course of the stock.
Given CRSP’s bleak financials, disappointing analyst expectations, low profitability, stretched valuation, and stiff competition, this biotech stock is best avoided now.

Throughout 2023, the U.S. stock market experienced several micro-cycles. From January to July, the SPDR S&P 500 ETF Trust (SPY), which tracks the performance of the S&P 500 index, advanced over 19% on a total return basis. However, in late October, nearly half that momentum had withered, with the Index briefly plunging into correction territory, indicating a 10% decline from July’s peaks.
The rising bond rate between late July and October contributed to the recent correction. The three-month period provided an adequate opportunity for investors to pivot away from stocks. Adding to the investors’ worries was Chair Jerome Powell’s comment: “The question of rate cuts just doesn’t come up.”
October witnessed the weakest performance in the S&P 500 since 2018 – its third successive month of contractions. This decline was perhaps predictable, considering the economic forecast concerns, stubborn inflation rate, prolonged apprehension over Federal Reserve policy rates, and geopolitical turmoil.
The financial picture brightened in November when stocks rallied robustly, nearly restoring the S&P 500 to its July peak. Making an impressive rebound in just 16 sessions, the S&P 500 effectively exited its correction phase, marking the swiftest turnaround since the 1970s.
As evidence of an overheated economy finally began to cool, investor tension eased, and the S&P 500 got a significant boost, surging by 8.5%. This surge brought its progress close to a 20% year-to-date increase, coinciding with the 10-year Treasury rates plunging below 4.5%.
Furthermore, another lower-than-expected inflation reading offers a flicker of hope that the contentious battle against inflation might soon abate.
As the Thanksgiving holiday curtails November’s U.S. trading week, investors are waiting to see if this resurgence in the stock market will endure until year’s end.
So, is the pathway clear?
While drawing definite conclusions could be too soon, let’s look at some promising indications suggesting the rally could persist until the close of the year…
After the Fed’s 20 months of stringent monetary policy tightening, it remains unclear to officials if the financial conditions are sufficiently restrictive to control inflation – a rate seen as surpassing the central bank’s 2% target.
Despite this uncertainty, the Fed maintains interest rates within the expected range of 5.25%-5.50%. Chairman Jerome Powell has not dismissed the possibility of further monetary tightening, leaving markets to ponder possible future actions of the Fed.
Forthcoming economic indicators will primarily guide decisions regarding future rate hikes. Depending upon inflation trends, there is potential for introducing interest rate cuts during the second quarter of 2024 or the following months.
If the Fed successfully facilitates a “soft landing” for the economy, implementing rate cuts while avoiding a recession, this could potentially set off a stock market rally. Conversely, investors might encounter unexpected skepticism if economic growth continues at its current pace and inflation returns in the following months.
Consumer spending is paid attention to, which, till now, has been crucial for sustaining economic growth amid climbing interest rates that often lead to economic slowdown. Historically, November has proven to be a strong month for the S&P 500, with an average yield of 0.88%, making it the third most lucrative month.
Historically, the S&P 500 recorded positive returns 68% of the time during Thanksgiving week, an achievement exceeding the average week. The sales recorded during Thanksgiving and Black Friday act as a barometer of market sentiment. Strong retail figures may herald the beginning of a robust shopping season, potentially boosting stock prices.
U.S. consumer spending accounts for about 70% of the economy. However, core U.S. retail sales registered a marginal increase of just 0.2% in October as higher borrowing costs and persistent effects of inflation curbed spending, leading to struggles for retail stocks. An uptick in sales could lay the groundwork for a December rally.
Displaying a notable robustness, the U.S. economy has continued to grow at over 2% annualized pace in the first and second quarters of 2023, surging to a 4.9% annualized growth rate in the third quarter. There is additional optimism as the GDPNow forecast for the fourth-quarter GDP has been revised upward to 2.1%.
Favorable economic circumstances like a robust employment market coupled with a resolute trend in consumer spending have contributed significantly to the sustainability of this positive economic momentum. Corporate earnings, too, reflected optimistic trends in the third quarter, a sign that economists regard as propitious.
Analysts are hopeful for a mildly favorable turn in earnings moving forward. While current economic metrics remain somewhat subdued, they do not signal an impending recession. Consequently, the equity market remains a scene of active engagement.
However, should investors be more cautious? Quite likely. Let’s understand why…
This year’s most optimistic occurrence was when the small-cap stocks in the Russell 2000 significantly eclipsed the returns of the SPY. Especially notable is the seemingly undervalued status of the small-cap index, which further intensifies with prospective Fed’s interest rate cuts scheduled for the first half of 2024. Historically,  debt-heavy small-caps perform well during Fed-induced rate reductions. Consequently, small-caps could potentially witness a significant boost as investors begin to speculate on the completion of the Fed’s interest rate hike cycle.
The sign of an assuredly bullish market is the heightened risk appetite, funneling investors toward smaller, growth-oriented companies. This pattern aligns with the traditional long-term advantage of small caps over large caps, an edge not witnessed in recent years.
However, certain risks continue to loom. Most significantly, small-caps’ vulnerability to recessions.
Despite Russel 2000’s attractive valuation, large-cap stocks have carried on their ascent while small caps are again underperforming, sparking questions regarding the genuine bullish nature of this market.
SPY’s promising gain offers encouragement. This arises from the fact that it’s challenging to maintain a confident bullish stance when all the gains are primarily accruing to the so-called ‘Magnificent 7’, previously known as FAANG. These stocks have mainly driven the market-cap-weight gain in the S&P 500 in recent years, leaving the rest of the stock and bond market on the sidelines.
Over the past year, one prevalent error among investors was underestimating the potential rise in price-to-earnings multiples, particularly for large-cap and mega-cap stocks like those comprising the ‘Magnificent 7.’
Furthermore, the era of viewing stocks as the sole viable investment option has waned. For the past two years, investors have experienced attractive returns through bonds or even by allocating a portion of their portfolio to a money-market fund, with several offering yields exceeding 5%.
Bottom Line
Within just three weeks of November, a significant shift occurred — from initial skepticism about the bull market’s validity to witnessing its first correction and ultimately seeing the S&P 500 Index rise to a new historical peak. A swift recovery saw stocks rise again, erasing the memory of the recent correction.
Every sector within the S&P 500 Index closed in positive territory, with more cyclical and economically sensitive industries leading the charges. This demonstrates the enduring expansion and robustness of the bull market, which, up until recently, has primarily been propelled by the strong performances of ‘Magnificent 7.’
With the current bullish trend and the anticipated positive impact of the holiday season, stocks could maintain their rally, even reaching previous high levels.
Bank of America Corporation’s strategists suggest that due to U.S. companies’ resilience in dealing with higher rates and macroeconomic disturbances, the S&P 500 is on track to reach a fresh peak in 2024. Meanwhile, RBC’s projection for the SPY’s EPS in 2024 stands at $232, indicating a promising trajectory for additional gains in the coming year.
However, the existing price of the index appears to already factor in the expected recovery in the SPY’s forecasted EPS for 2024. Therefore, it may not be sufficient to drive the index’s growth at this year’s remarkable pace. It should also be noted that potential factors like a recession or emergent political or geopolitical unrest could pose further complications. Therefore, investors should tread with caution.